TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06541067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole
Description: Per Os, on Day 0 of allo-CSH if the patient's condition permits, or after the last dose of immunosuppressor (post-transplant cyclophosphamide) (Day+5 or Day+6 depending on protocols).~On the first day of treatment: 300 mg in the morning (= 3 x 100 mg tablets) and 300 mg in the evening (= 3 x 100 mg tablets), then from day 2 of treatment: 300 mg per day (= 3 x 100 mg tablets) in a single dose
Study: NCT06451614

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpaceIT Hydrogel System
Description: SpaceIT Hydrogel System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of SpaceIT Hydrogel System to reduce the radiation dose delivered to the anterior rectum. The SpaceIT Hydrogel System is composed of a radiopaque, biodegradable material designed to maintain space for approximately 12 weeks and be absorbed in about 6 months, sufficient time to support the intended use.~SpaceIT has an iodinated PEG powder making it radiopaque.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Commercially available Boston Scientific Spacer
Description: Boston Scientific's commercially available SpaceOAR Hydrogel System or SpaceOAR Vue Hydrogel System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of SpaceOAR Hydrogel System or SpaceOAR Vue Hydrogel System to reduce the radiation dose delivered to the anterior rectum. SpaceOAR and SpaceOAR Vue are both perirectal spacers. SpaceOAR Vue specifically has an iodinated PEG powder making it radiopaque. SpaceOAR does not contain iodinated PEG powder and is not radiopaque. The SpaceOAR Hydrogel System or SpaceOAR Vue Hydrogel System maintains space during prostate radiotherapy treatment and is completely absorbed by the patient's body over time.
Study: NCT06374667

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Y-3 ICO injection
Description: Patients included will be given skull outer plate drilling surgery and Y-3 ICO injection under local anesthesia and sedation. The injection will be given for 3 consecutive days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Y-3 intravenous injection
Description: Patients included will be given Y-3 intravenous injection for 7 consecutive days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: standard treatment and management according to related guidelines during the entire treatment period

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: standard treatment and management according to related guidelines during the entire treatment period
Study: NCT06185192

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Viome's Precision Nutrition Program (VPNP)
Description: Nutrition, diet, and possible coaching through Viome application. Precision supplement based on the participants microbiome sample results.
Study: NCT06505239

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: FSD-F2R6-A-CP
Description: FSD-F2R6-A-CP is a unique dietary supplement with natural ingredients, vitamins and minerals that potentially enhances cognition, replenishes cofactors needed for alcohol metabolism and may accelerate alcohol metabolism in the body.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drink designed to match FSD-F2R6-A-CP in color and taste.
Study: NCT05929859

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech Motor Chaining
Description: Sessions begin with Pre-practice to elicit target sounds, with verbal cueing and shaping strategies. During Structured Practice, items are practice in blocks of 6 consecutive trials (with systematic increases in difficulty), and our web-based software will manipulate the principles of motor learning, including the stimulus prompt, the participant's production, analysis of the clinician's rating, feedback prompts for the clinician, and the variability present in the practice trial. Randomized Practice will also be guided by the software and includes all linguistic levels that were produced correctly during Structured Practice, with items presented in random order.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech Motor Chaining
Description: Sessions begin with Pre-practice to elicit target sounds, with verbal cueing and shaping strategies. During Structured Practice, items are practice in blocks of 6 consecutive trials (with systematic increases in difficulty), and our web-based software will manipulate the principles of motor learning, including the stimulus prompt, the participant's production, analysis of the clinician's rating, feedback prompts for the clinician, and the variability present in the practice trial. Randomized Practice will also be guided by the software and includes all linguistic levels that were produced correctly during Structured Practice, with items presented in random order.
Study: NCT05685173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odronextamab
Description: Odronextamab will be administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5837
Description: REGN5837 will be administered by IV infusion
Study: NCT05044312

Intervention type: OTHER
Group type: OTHER
Intervention: Sleeping Disturbances
Description: most common complaints of patients after surgery and may affect the ability to carry out daily activities, quality of life, and post-surgery recovery.
Study: NCT05273788

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2400 ThorS-MagNT Stimulations at 1Hz
Description: The inferior angles of the scapula will serve as landmarks for the T7 level. A mapping procedure is performed with subject in the seated position using a single-pulse stimulation circular 90- mm coil to determine the location and minimum intensity of stimulation left and right of the T7 spinous process required to achieve a motor evoked response (MEP) of 50 μV with 50% of trials (resting motor threshold) in the upper rectus abdominis or external oblique muscles. The intensity for ThorS-MagNT is set at 150% above motor threshold. 1 Hz ThorS-MagNT, one of 4 total trains is delivered over 5 minutes with 3-min rest intervals on both right and left sides (total 1200 pulses/side).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2400 ThorS-MagNT Stimulations at 10Hz
Description: The inferior angles of the scapula will serve as landmarks for the T7 level. A mapping procedure is performed with subject in the seated position using a single-pulse stimulation circular 90- mm coil to determine the location and minimum intensity of stimulation left and right of the T7 spinous process required to achieve a motor evoked response (MEP) of 50 μV with 50% of trials (resting motor threshold) in the upper rectus abdominis or external oblique muscles. The intensity for ThorS-MagNT is set at 150% above motor threshold. 10Hz ThorS-MagNT involves delivering one train of 100 pulses per minute with 50-second rest intervals over twelve minutes on both right and left sides (total 1200 pulses/side).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulations
Description: The inferior angles of the scapula will serve as landmarks for the T7 level. A mapping procedure is performed with subject in the seated position using a single-pulse stimulation circular 90- mm coil to determine the location and minimum intensity of stimulation left and right of the T7 spinous process required to achieve a motor evoked response (MEP) of 50 μV with 50% of trials (resting motor threshold) in the upper rectus abdominis or external oblique muscles. The intensity for ThorS-MagNT is set at 150% above motor threshold. Sham stimulations, one of 4 total trains is delivered over 5 minutes with 3-min rest intervals on both right and left sides (total 1200 pulses/side).
Study: NCT06515912

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ketogenic Diet
Description: A ketogenic diet with 5% carbohydrate, 18% protein, and 77% fat by percent kcal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet
Description: A ketogenic diet with 5% carbohydrate, 18% protein, and 77% fat by percent kcal.
Study: NCT06459024

Intervention type: OTHER
Intervention: Registration into the STREAM platform
Description: All patients fulfilling eligibility criteria will be registered into the STREAM platform. Baseline and follow up information will be recorded for each patient enrolled. Each patient will be followed up according to normal clinical practice up to 4 years.
Study: NCT06256640

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mandibular advancement Device
Description: Intra oral appliances and more specifically Mandibular Advance Devices (MAD) are one of the established alternatives to treat OSA. Oral appliances and MAD are often used interchangeably but we prefer to call them MAD as it is more descriptive of its mechanism of action. MAD are placed in the mouth to temporarily advance and stabilize the lower jaw forward in order to keep the airway open during sleep.
Study: NCT06224673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARX788
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARX788
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARX788
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Description: Undergo CT or Positron Emission Tomography(PET)/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Description: Undergo CT or Positron Emission Tomography(PET)/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Description: Undergo CT or Positron Emission Tomography(PET)/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiloride
Description: Ophthalmologic drops given topically to participants for an eye toxicity substudy
Study: NCT05184816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferoxamine (DFO)
Description: The accelerated single-patient dose escalation will apply to dosing cohorts 1 through 4 (10mg, 30mg, 60mg, 100mg) and will convert to a 3+3 dose escalation for cohorts 5 through 9 (150mg, 210mg, 280mg, 372mg, 495mg).
Study: NCT06385353

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quantification of deep vein thrombosis burden and assessment of post-thrombotic syndrome
Description: Post-thrombotic syndrome will be assessed by the Villalta score until 6 months of follow-up.~Data collected from colour doppler ultrasound will be used to calculate the Venous Volumetric Index to quantify deep vein thrombosis burden until 6 months of follow-up.
Study: NCT04981600

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: Patients in the RF group will be first examined under anesthesia at the beginning of the procedure in lithotomy position. Approximately 3-6 ml of 20 mg/ml Lidocaine (Jetokaine, Adeka İlaç Sanayi, Samsun) solution will be injected between the cushion and the internal anal sphincter to minimize heat conduction to the surrounding tissues during the procedure. The HPR45i probe (F Care Systems, Antwerpen, Belgium) connected to the Rafaelo ® EVRF machine (F Care Systems, Antwerpen, Belgium) will be placed inside the cushion and 25 watts of RF energy will be transmitted. Care will be taken by not exceeding the dentate line caudally. The recommended Joule value for each operation is 1200-3000 J. Then cold is applied on the cushion, reducing the temperature of the tissue and preventing damage to the surrounding tissues. The same procedure will be performed for other pathologic cushions as well.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser
Description: The same preoperative preparations will be done for the laser group as well. The NeoV 1470 (neoLaser, Israel) device will be used in this group. Following routine placement of the patient in lithotomy position and determining the cushion to be treated, a 12 W laser beam with a wavelength of 1470nm will be inserted into the cushion above the dentate line and advanced to the apex and approximately 3 laser shots are delivered throughout the course caudally, the number of which can be altered according to the size targeted cushion. Finally the procedure will be completed after gentle cold application.~An enema will be given to the patients in both study groups in the morning of the operation and patients will be discharged with analgesics on the same day.
Study: NCT05789082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divarasib
Description: Participants will receive one of two doses of divarasib orally (PO), QD on days 1-21 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divarasib
Description: Participants will receive one of two doses of divarasib orally (PO), QD on days 1-21 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Participants will receive a 200 mg IV infusion of pembrolizumab Q3W on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Participants will receive a 200 mg IV infusion of pembrolizumab Q3W on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Participants will receive IV carboplatin Q3W for four 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Participants will receive IV cisplatin Q3W for four 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Participants will receive IV pemetrexed Q3W.
Study: NCT05948995

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abduction external rotation brace
Description: Abduction external rotation brace Arm position : Abduction , External rotation
Study: NCT04954885

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo stool sample

Intervention type: OTHER
Intervention: Physical Performance Testing
Description: Undergo short physical performance battery

Intervention type: OTHER
Intervention: Physical Performance Testing
Description: Perform 6-minute walk test

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT05646836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cevostamab
Description: Cevostamab will be administered intravenously on a 28-day cycle, for up to one year of treatment depending on clinical response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cevostamab
Description: Cevostamab will be administered intravenously on a 28-day cycle, for up to one year of treatment depending on clinical response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XmAb24306
Description: XmAb24306 will be administered intravenously on a 28-day cycle, for up to one year of treatment depending on clinical response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.
Study: NCT05039866

Intervention type: BIOLOGICAL
Intervention: ST-920
Description: No study drug is administered in this study. Subjects who received ST-920 in a separate parent trial will be evaluated in this trial for long-term safety.
Study: NCT06421766

Intervention type: DEVICE
Intervention: BAHS
Description: Implantation of a percutaneous bone-anchored hearing system

Intervention type: DEVICE
Intervention: BAHS
Description: Implantation of a percutaneous bone-anchored hearing system
Study: NCT06314243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pumpkin Seed Oil  Ronkin®, KMT PHARMA, Egypt. 
Description: Ronkin soft gelatin capsules, each containing 1010 mg of pumpkin seed oil (Latin name: Curcurbita pepo), standardized to contain palmitic acid (8-15%), stearic acid (3-8%), oleic acid (15-35%), linoleic acid (40-65%), and other fatty acids (≤ 2.4%)
Study: NCT05920889

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: 0.5mg subcutaneous injection of the drug before or during EVT, and 7 days after the procedure. i.e. patient will receive a total of 2 injections.
Study: NCT05955846

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cataract surgery
Description: Subjects will undergo surgery to remove cataract (natural cloudy lens) via phacoemulsification implant the IOL Both eyes will be treated one month apart. Subjects will be followed up during 12 months

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: implantation of device IOL FG-80030.1
Description: implant the IOL in both eyes. Both eyes will be treated one month apart. Subjects will be followed up during 12 months
Study: NCT05284409

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pethidine
Description: 36 patients will receive 0.5 mg/kg Pethidine IVI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 36 patients will receive 15 mg/kg Acetaminophen IVI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 36 patients will receive 0.1 mg/kg Dexamethasone IVI
Study: NCT03463239

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous tissue engineered corpora
Description: penile tissue construct
Study: NCT04781855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT05660785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herombopag
Description: Hetrombopag is a TPO receptor agonist approved in China in 2021 for idiopathic thrombocytopenic purpura (ITP) and second-line severe aplastic anemia (SAA). Indications of chemotherapy-induced thrombocytopenia (CIT), pediatric/juvenile ITP and naive severe aplastic anemia are under development. Hetrombopag was granted Orphan Drug Designation by FDA for the treatment of CIT.~Cyclosporine A is a calcineurin inhibitor, which has an effect on reducing T-cell proliferation and activation, can reverse pancytopenia and alleviate transfusion requirements in NSAA.
Study: NCT04573530

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: We Walk Plus Intervention
Description: The frequency and content of weekly personalized SMS are based on each participant's preference. Prior to implementation of intervention, the investigators will conduct focus groups to learn participants' social network activities and preferences, strategies that can be used to encourage engagement via a private Fitbit community network.
Study: NCT06498648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluorothymidine F-18
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluorothymidine F-18
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluorothymidine F-18
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan